Skip to main content
SpringerLink
Log in

Achtung Wechselwirkungsrisiken

Supportivtherapeutika und Onkologika

  • Fortbildung
  • Published:
Im Focus Onkologie Aims and scope

In den letzten Jahren hat das Thema Arzneimittelwechselwirkungen und Sicherheit von Arzneimitteltherapien (AMTS) in der Onkologie zunehmend an Bedeutung gewonnen. Die Spannbreite der jeweiligen klinischen Konsequenzen ist teilweise beträchtlich. Interessant ist in diesem Zusammenhang eine Fokussierung auf den Einsatz von Supportivtherapeutika, mit denen die Nebenwirkungen einer Tumortherapie oder der Krebserkrankung an sich gelindert werden sollen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1:

Literatur

  1. Lipp HP. Klinisch relevante Wechselwirkungen in der Onkologie. PZ Prisma. 2009;16:219–32.

    CAS  Google Scholar 

  2. John C, Rose O. Gastroösophageale Refluxkrankheit — Grundlagen für das Medikationsmanagement. DAZ. 2014;154(32):3399–408.

    Google Scholar 

  3. Herbrink M et al. Variability in bioavailability of small molecular tyrosine kinase inhibitors. Cancer Treat Rev. 2015;41(5):412–22.

    Article  CAS  PubMed  Google Scholar 

  4. Lipp HP. Klinisch-pharmakokinetische und physikochemische Interaktionen mit niedermolekularen, zielgerichtet wirksamen Tumortherapeutika. Krankenhauspharmazie. 2017. [in Druck].

  5. Yu H et al. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. Clin Pharmacokinet. 2014;53(4):305–25.

    Article  CAS  PubMed  Google Scholar 

  6. Sun J et al. Concomitant Administration of Proton Pump Inhibitors and Capecitabine is Associated With Increased Recurrence Risk in Early Stage Colorectal Cancer Patients. Clin Colorectal Cancer. 2016;15(3):257–63.

    Article  PubMed  Google Scholar 

  7. Chu MP et al. Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial. JAMA Oncol. 2016 Oct 13. [Epub ahead of print].

  8. Lugini L et al. Proton pump inhibitors while belonging to the same family of generic drugs show different anti-tumor effect. J Enzyme Inhib Med Chem. 2016;31(4):538–45.

    CAS  PubMed  Google Scholar 

  9. Chen YM et al. Antacid Use and De Novo Brain Metastases in Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Were Treated Using First-Line First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. PLoS One. 2016;11(2):e0149722.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Savarino V et al. The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal. Eur J Intern Med. 2016 Oct 23. pii: S0953-6205(16)30362-4.

  11. Planchard D. Can an Acidic Beverage Reduce Interactions Between Proton Pump Inhibitors and Erlotinib? J Clin Oncol. 2016;34(12):1292–4.

    Article  CAS  PubMed  Google Scholar 

  12. Yago MR et al. The Use of Betaine HCI to Enhance Dasatinib Absorption in Healthy Volunteers with Rabeprazole-Induced Hypochlorhydria. AAPS Journal. 2014;16:1358–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Lipp HP. NEPA (Netupitant/Palonosetron) zur Prophylaxe der Chemotherapie-induzierten Nausea und Emesis. Krankenhauspharmazie. 2015;36(10):485–93.

    Google Scholar 

  14. Navari RM, Aapro M. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016;374(14):1356–67.

    Article  CAS  PubMed  Google Scholar 

  15. Hiemke C, Eckermann G. Kombinationstherapie/Polypharmazie: Interaktionen von Psychopharmaka. Arzneimitteltherapie. 2014;32(12):361–70.

    Google Scholar 

  16. Lee KB et al. Cannabis smoking and sildenafil citrate induced acute coronary syndrome in a patient with myocardial bridge. Anadolu Kardiyol Derg. 2013;13(2):180–1.

    PubMed  Google Scholar 

  17. Bernard SA, Bruera E. Drug interactions in palliative care. J Clin Oncol. 2000;18(8):1780–99.

    CAS  PubMed  Google Scholar 

  18. Donneyong MM et al. Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study. BMJ. 2016;354:i5014.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Juurlink D. Revisiting the drug interaction between tamoxifen and SSRI antidepressants. BMJ. 2016;354:i5309.

    Article  PubMed  Google Scholar 

  20. Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry. 2009;70(12):1688–97.

    Article  CAS  PubMed  Google Scholar 

  21. Dezentjé VO et al. CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects. Breast Cancer Res Treat. 2015;153(3):583–90.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Fasinu PS et al. An overview of the evidence and mechanisms of herb-drug interactions. Front Pharmacol. 2012;3:69.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fachapotheker für klinische Pharmazie, Universitätsklinikum Tübingen, Tübingen, Deutschland

    Hans-Peter Lipp

Authors
  1. Hans-Peter Lipp
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hans-Peter Lipp.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lipp, HP. Supportivtherapeutika und Onkologika. Im Focus Onkologie 20, 44–49 (2017). https://doi.org/10.1007/s15015-017-3111-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-017-3111-7

Search

Navigation